CRISPR/Cas9 Targeting of ABCB1 Reverses Tumor Drug Resistanc
2026-04-13
CRISPR/Cas9 Targeting of ABCB1 Reverses Tumor Drug Resistance
Study Background and Research Question
Multidrug resistance (MDR) is a major barrier to effective cancer chemotherapy, often driven by overexpression of efflux transporters such as ABCB1 (also known as MDR1 or P-glycoprotein). ABCB1 actively transports a broad spectrum of chemotherapeutic drugs—including taxanes, vinca alkaloids, and anthracyclines—out of cancer cells, reducing intracellular drug accumulation and efficacy. Traditional approaches to inhibit MDR have faced specificity and toxicity hurdles. In this context, the referenced study [Yang et al., Am J Transl Res 2016;8(9):3986-3994, http://www.ajtr.org/files/ajtr0035352.pdf] investigates whether CRISPR/Cas9 genome editing can specifically and efficiently disrupt ABCB1, thereby reversing MDR phenotypes in cancer cells.Key Innovation from the Reference Study
The core innovation lies in applying RNA-guided CRISPR/Cas9 technology to precisely knockout the ABCB1 gene in established MDR tumor cell lines. Unlike previous pharmacological inhibitors or genetic knockdowns, CRISPR/Cas9-mediated editing enables irreversible loss-of-function at the genomic level. This direct targeting of the genetic root of MDR represents a significant advance over transient or less-specific strategies. The study is among the first to demonstrate that targeted genome editing can restore drug sensitivity by disrupting a clinically relevant resistance gene.Methods and Experimental Design Insights
The investigators selected two well-characterized MDR cancer cell lines—KBV200 and HCT-8/V—both of which overexpress ABCB1 and exhibit robust drug efflux activity. To disrupt ABCB1, they designed two single-guide RNAs (sgRNAs) targeting exonic sequences critical for gene function. The sgRNAs were delivered with Cas9 via plasmid transfection, and successful editing was confirmed through sequencing and loss of ABCB1 protein expression. Cell viability and drug sensitivity were assessed using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) assay, a standard colorimetric method for metabolic activity measurement and cytotoxicity determination [product_spec: https://www.apexbt.com/mtt.html]. Intracellular accumulation of chemotherapeutics (doxorubicin, rhodamine 123) was quantified to verify the functional restoration of drug uptake.Protocol Parameters
- assay | MTT colorimetric cell viability assay | value_with_unit | 0.5–1.0 mg/mL MTT in culture medium | applicability | in vitro assessment of drug sensitivity and metabolic activity in MDR cancer cells | rationale | MTT is reduced by NADH-dependent oxidoreductases in viable cells, producing quantifiable formazan correlating with cell viability | source_type: product_spec | source_link: https://www.apexbt.com/mtt.html
- assay | Drug exposure | value_with_unit | 24–72 h incubation with chemotherapeutic agents (e.g., vincristine, doxorubicin) | applicability | determines cytotoxic response pre- and post-ABCB1 knockout | rationale | Standard incubation times to assess acute and longer-term drug effects | source_type: paper | source_link: http://www.ajtr.org/files/ajtr0035352.pdf
- assay | sgRNA-Cas9 transfection | value_with_unit | 1–2 μg plasmid DNA per well in 6-well plates | applicability | genome editing of ABCB1 in cultured cells | rationale | Sufficient plasmid DNA for robust transfection and gene editing | source_type: paper | source_link: http://www.ajtr.org/files/ajtr0035352.pdf
Core Findings and Why They Matter
CRISPR/Cas9-mediated knockout of ABCB1 in both KBV200 and HCT-8/V cell lines led to a marked loss of P-glycoprotein expression, confirmed by immunoblotting and sequencing [source_type: paper; source_link: http://www.ajtr.org/files/ajtr0035352.pdf]. Functionally, edited cells exhibited:- Significantly increased sensitivity to ABCB1 substrate drugs (vincristine, doxorubicin), with lower half-maximal inhibitory concentration (IC50) values compared to parental MDR cells [source_type: paper; source_link: http://www.ajtr.org/files/ajtr0035352.pdf].
- Substantially increased intracellular accumulation of rhodamine 123 and doxorubicin, indicating loss of active efflux activity [source_type: paper; source_link: http://www.ajtr.org/files/ajtr0035352.pdf].
Comparison with Existing Internal Articles
Multiple internal resources underscore the importance of MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) in metabolic activity measurement and cell proliferation assays:- Gold-Standard Tetrazolium Salt for Cell Viability Assays highlights MTT’s benchmark status for quantitative cell viability assessment in drug screening workflows, closely paralleling methodologies in the CRISPR/ABCB1 study.
- Scenario-Based Guide to MTT addresses optimization and troubleshooting, relevant for researchers adapting CRISPR-based screens to various cell types.
- Rapid Metabolic Activity Measurement discusses MTT’s sensitivity and adaptability, providing workflow recommendations for cytotoxicity and apoptosis studies—directly applicable to MDR investigations.